Back to Search Start Over

Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance.

Authors :
Kalpadakis, Christina
Pangalis, Gerassimos A.
Sachanas, Sotirios
Tsirkinidis, Pantelis
Kontopidou, Flora N.
Moschogiannis, Maria
Yiakoumis, Xanthi
Koulieris, Efstathios
Dimopoulou, Maria N.
Kokkoris, Stella I.
Kyrtsonis, Marie-Christine
Siakantaris, Marina P.
Tsourouflis, Gerassimos
Korkolopoulou, Penelope
Rontogianni, Dimitra
Tsaftaridis, Panagiotis
Plata, Eleni
Papadaki, Helen A.
Panagiotidis, Panagiotis
Angelopoulou, Maria K.
Source :
Blood. 8/9/2018, Vol. 132 Issue 6, p666-670. 5p.
Publication Year :
2018

Abstract

The article discusses the treatment of splenic marginal zone lymphoma (SMZL) and the lack of randomized trials, highlighting the use of rituximab infusions for the treatment. It examines the bone marrow for complete response (CR), the impact of rituximab on the disease progression, and the overall survival (OS) rate.

Subjects

Subjects :
*LYMPHOMA treatment
*RITUXIMAB
*RESPONSE rates
BONE marrow examination
PREVENTION of disease progression

Details

Language :
English
ISSN :
00064971
Volume :
132
Issue :
6
Database :
Academic Search Index
Journal :
Blood
Publication Type :
Academic Journal
Accession number :
131202760
Full Text :
https://doi.org/10.1182/blood-2018-02-833608
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details